Comparison 5. Alpha‐blocker and usual care versus usual care: alpha‐blocker type subgroup.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
5.1 Stone clearance	35	3999	Risk Ratio (M‐H, Random, 95% CI)	1.16 [1.09, 1.23]
5.1.1 Tamsulosin	31	3465	Risk Ratio (M‐H, Random, 95% CI)	1.17 [1.09, 1.25]
5.1.2 Terazosin	1	120	Risk Ratio (M‐H, Random, 95% CI)	1.05 [0.87, 1.26]
5.1.3 Silodosin	2	54	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.46, 2.26]
5.1.4 Alfuzosin	3	254	Risk Ratio (M‐H, Random, 95% CI)	1.12 [0.89, 1.40]
5.1.5 Naftopidil	1	27	Risk Ratio (M‐H, Random, 95% CI)	3.37 [0.50, 22.69]
5.1.6 Doxazosin	1	79	Risk Ratio (M‐H, Random, 95% CI)	1.19 [1.00, 1.41]
5.2 Auxiliary treatment	12	1251	Risk Ratio (M‐H, Random, 95% CI)	0.67 [0.45, 1.00]
5.2.1 Tamsulosin	10	1112	Risk Ratio (M‐H, Random, 95% CI)	0.71 [0.46, 1.08]
5.2.2 Doxazosin	1	79	Risk Ratio (M‐H, Random, 95% CI)	0.28 [0.06, 1.21]
5.2.3 Silodosin	1	60	Risk Ratio (M‐H, Random, 95% CI)	1.77 [0.08, 41.65]
5.3 Major adverse events	7	747	Risk Ratio (M‐H, Random, 95% CI)	0.60 [0.46, 0.80]
5.3.1 Tamsulosin	6	687	Risk Ratio (M‐H, Random, 95% CI)	0.60 [0.45, 0.80]
5.3.2 Silodosin	1	60	Risk Ratio (M‐H, Random, 95% CI)	1.77 [0.08, 41.65]